Literature DB >> 2431582

Tissue distribution of aromatic retinoid (etretinate) in three autopsy cases: drug accumulation in adrenals and fat.

A Vahlquist, O Rollman, I Pihl-Lundin.   

Abstract

The problematic storage of etretinate in fat during chronic etretinate therapy prompted us to search for other "high-affinity" tissues in 3 patients studied at autopsy. Specimens from eleven organs were analysed for etretinate and its main metabolite, etretin, by high-performance liquid chromatography. The results confirmed an accumulation of etretinate in fat and to a lesser degree in liver. High levels of etretinate were also found in the adrenals and, in one case, this value exceeded that of the fat tissue. Low levels were observed in several other organs, notably the kidneys, brain and testis. With the possible exception of liver and gut, the metabolite did not accumulate in any particular organ. Although the available data is still limited, the risk that the accumulation of etretinate in the adrenals may adversely affect adrenal function must be examined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431582

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  3 in total

Review 1.  Acitretin (Neotigason). A review of pharmacokinetics and teratogenicity and hypothesis on metabolic pathways.

Authors:  M L Bouvy; M C Sturkenboom; M C Cornel; L T De Jong-Van den Berg; B H Stricker; H Wesseling
Journal:  Pharm Weekbl Sci       Date:  1992-04-24

2.  Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment.

Authors:  M C Sturkenboom; L T de Jong-Van Den Berg; P C van Voorst-Vader; M C Cornel; B H Stricker; H Wesseling
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

3.  Acitretin : A Review of its Pharmacology and Therapeutic Use.

Authors:  Tania Pilkington; Rex N Brogden
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.